Verzenio vs Kisqali
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Verzenio | US Kisqali | |
|---|---|---|
| Generic name | abemaciclib | ribociclib |
| Drug class | CDK4/6 Inhibitor | CDK4/6 Inhibitor |
| Treats | HR+/HER2- breast cancer | HR-positive, HER2-negative breast cancer |
| Category | Oncology | Oncology |
| Manufacturer | Eli Lilly | Novartis |
| Year approved | 2017 | 2017 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $85M | $80M |
| Common side effects | Diarrhea, Low blood counts, Fatigue, Blood clots | Low white blood cells, Nausea, Fatigue, Heart rhythm changes (QT) |
Frequently asked questions
Is Verzenio or Kisqali better?
Neither is universally "better." Verzenio (abemaciclib) and Kisqali (ribociclib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Verzenio and Kisqali?
Verzenio is a CDK4/6 Inhibitor made by Eli Lilly, while Kisqali is a CDK4/6 Inhibitor made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Verzenio has the larger estimated TV advertising budget of the two.